Clinical Trial Update: Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating thalidomide in combination with temozolomide (Temodar) for neuroendocrine tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Drugs mentioned

• Temodar (Temozolomide)
• Thalidomide (thalidomide)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Neuroendocrine Tumor | Phase 2 | Status: COMPLETED